Navigation Links
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Date:2/16/2012

LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ --

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90) inhibitor Debio 0932. Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in the second quarter of 2012.

"Our team has been very pleased with the development of Debio 0932, which has become an important molecule in Debiopharm's pipeline," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We believe that HSP90 represents an important molecular target in cancer therapy, and we are eager to advance this molecule in the Phase Ib clinical trial, as well in our planned Phase I/II studies, which we hope will yield important new data for the further development of Debio 0932."

"We have been highly impressed with the depth of Debiopharm's development expertise and commitment to furthering Debio 0932 into additional clinical studies in 2012," said Dan Passeri, Curis President and Chief Executive Officer. "Importantly, we continue to be very pleased with the clinical results that have been observed to-date, and we look forward to reporting further progress on this molecule in the future."

About the Phase I Clinical Trial

Debiopharm initiated a Phase I clinical trial in April 2010 that was designed to evaluate the maximum tolerated dose and safety of Debio 0932. The first part of the study (Phase Ia), an open-label,
'/>"/>

SOURCE The Debiopharm Group and Curis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
2. Continuity as Debiopharm Group™ Management Moves Forward
3. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
4. Debiopharm Group™ and Aurigene Nominate Development Candidate
5. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
6. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
7. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
11. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Saint-Gobain has acquired ZenPure, a ... products, mainly for the life sciences sector. ... a state-of-the-art plant in Hangzhou, China ... globe and will bolster the range of fluid systems ... is fully in line with the Group,s strategy of ...
(Date:5/6/2015)... KENNEBUNK, Maine , May 6, 2015  Membership ... 2014, according to a Healthcare Business Strategy report ... plans, also known as Medigap or Med Supp ... December 31, 2014, a 5.2% increase from 2013. ... plans increased by 551,135 covered lives.  Though UnitedHealth ...
(Date:5/6/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7qn2gf/global_insulin ... "Global Insulin Patch Market Opportunity Analysis" report ... like ultrasound and iontophoresis are being used for ... the type of technique, their prices may vary ... patients. In long-term, it would be considered as ...
Breaking Medicine Technology:Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Global Insulin Patch Market Opportunity Analysis 2015 2
... SPARTANBURG, S.C., Dec. 21, 2011 The jury verdict ... Ortho-McNeil-Janssen Pharmaceuticals and Johnson & Johnson, Inc. has been ... groundbreaking $327 million in civil penalties against the manufacturers ... announced the rulings on December 20 through two written ...
... 21, 2011   Uptake Medical ® today announced that ... its InterVapor ™ System for endoscopic lung volume ... the first non-surgical, endoscopic lung volume reduction system for ... natural healing processes without leaving implants or foreign materials ...
Cached Medicine Technology:Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied 2Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 2Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 3
(Date:5/6/2015)... Springs, Texas (PRWEB) May 06, 2015 ... stages of the HIMSS EMR Adoption Model, the ... paper, improve patient engagement and automate processes. The ... transitioned from paper-driven to electronic workflows, patient registration ... hard copies of consents. With HIMSS Stage 7 ...
(Date:5/6/2015)... 06, 2015 A quality built chicken coop condo ... yet practical way to raise chickens on a pasture. By ... Condo, it will have a chicken tractor that stands up to ... many years, as it is able to flex to uneven ground ... of the land are fertilized, and it will help provide the ...
(Date:5/6/2015)... 2015 Experienced Vancouver air conditioning installation ... that they will now conduct their cooling services, including ... addition to commercial and residential units. Strata complex air ... lot of technical knowledge as well as a professionally ... we will take away any old air conditioning unit ...
(Date:5/6/2015)... Chesapeake, Va. (PRWEB) May 06, 2015 ... hospital in the state of Virginia to acquire ... Vinci® surgical robot. The system upgrade includes enhanced ... many minimally invasive procedures across a wide spectrum ... surgical options, reduced pain and quicker recovery times. ...
(Date:5/6/2015)... Prime Pacific Health Innovations, the ... announce a new series of universal, one-time-use speculum ... footprint while improving treatment efficacy and saving therapists ... the world’s first waste hose designed specifically for ... claims the company’s president, Mr. Delmar Vogel. , ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3
... First and Only Site Allows Patients to See How Drugs Actually Work ... ... PRINCETON, N.J., April 30 Today, iGuard.org, a free,patient-driven online healthcare community, ... a new level. With,almost half of all Americans taking prescription drugs, and ...
... Ind., April 30 Hillenbrand, Inc.,(NYSE: HI ) ... first dividend as a publicly traded company of $0.1825 ... payable June 30, 2008 to,shareholders of record at the ... decision by our board to approve this inaugural dividend ...
... National Pet Week, May,4-10, celebrates the relationships ... opportunity to emphasize the caretaking actions we can ... care as recommended by,your veterinarian; giving them plenty ... for your pets safe and pleasant., "Being ...
... Houston, Tex. April 30, 2008 - Despite the ... in critically ill heart failure patients, implantation of these ... for high-volume blood transfusions during and immediately after surgery. ... suggesting that the incidence of these complications may be ...
... They Don,t Fully Understand the Details ... of Their Health Insurance Plan, WESTLAKE ... insurers across the U.S., yet,contacting plan members regularly and increasing their ... ratings,more renewal business and additional sales of services to members,according to ...
... the cross hairs of radiation or chemotherapy may be ... jammed, say University of Florida scientists writing in a ... fly cells discovered that slight changes in the protein ... aptly named for their roles in triggering cell death ...
Cached Medicine News:Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 2Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 3Health News:Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 6Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 7Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 8Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 9Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 10Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 11Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 12Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 13Health News:'Destruct' triggers may be jammed in tumor cells, UF geneticists say 2
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... dedicated high performance bio imaging system for ... of imaging chemiluminescent samples. It provides superbly ... use, thanks to new, unique image analysis ... the standard Genegnome, the Genegnome HR has ...
Medicine Products: